Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid to prevent periprosthetic bone loss after cementless hip arthroplasty in postmenopausal women
2006-002557-68Phase 3Completed
- Sponsor
- Hospital District of Southwest Finland
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Periprosthetic bone loss (PBL) and primary coxarthrosis comparing Zoledronic acid with Placebo (2 arms). Primary endpoint: Periprosthetic bone mineral loss by DXA. Started Aug 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Periprosthetic bone loss (PBL)primary coxarthrosis
Beyond the preview
Go deeper on 2006-002557-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002557-68.